A Phase I, Open-Label, Fixed Sequence Study to Investigate the Effect of Cytochrome P450 2D6 Inhibition on the Pharmacokinetics of Ulotaront in Healthy Subjects.

导出 OA

翻译打印收藏纠错

第一作者： Hironobu,Tsukada

第一单位： Sumitomo Pharma America, 84 Waterford Dr., Marlborough, MA, 01752, USA.;Sumitomo Pharma Co., Ltd, Tokyo, Japan.

作者： Hironobu,Tsukada ^[1] ; Yu-Luan,Chen ^[2] ; Guangqing,Xiao ^[2] ; Lisa,Lennek ^[2] ; Snezana M,Milanovic ^[2] ; MaryAlice,Worden ^[2] ; Daniel G,Polhamus ^[3] ; Yu-Yuan,Chiu ^[2] ; Seth C,Hopkins ^[2] ; Gerald R,Galluppi ^[4]

作者单位： Sumitomo Pharma America, 84 Waterford Dr., Marlborough, MA, 01752, USA.;Sumitomo Pharma Co., Ltd, Tokyo, Japan. ^[1] Sumitomo Pharma America, 84 Waterford Dr., Marlborough, MA, 01752, USA. ^[2] Metrum Research Group, Tariffville, CT, USA. ^[3] Sumitomo Pharma America, 84 Waterford Dr., Marlborough, MA, 01752, USA. gerald.galluppi@sunovion.com. ^[4]

主题词人类(Humans);细胞色素P450 CYP2D6(Cytochrome P-450 CYP2D6);帕罗西汀(Paroxetine);药物相互作用(Drug Interactions);酶抑制剂(Enzyme Inhibitors);曲线下面积(Area Under Curve)

DOI 10.1007/s40262-023-01317-4

PMID 37882999

发布时间 2024-04-16

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交